Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 2511-2520 Newer>

Pharmaceutical Executive October 1, 2005 Christopher Lisanti	Physician Frustration Doctors have had enough. But reps can still redeem themselves. As the industry thinks about new sales force models, it should look beyond ROI numbers, toward a new paradigm that not only works for pharma, but also for its customers.
Pharmaceutical Executive October 1, 2005 Jeffrey D. Abbey	Considering Intangibles Biotech partnerships among scientists, academic institutions, and pharma companies provide many challenges, including identifying the right partners, developing strong relationships to overcome hurdles, and dealing with cultural differences in an increasingly global market.
Pharmaceutical Executive October 1, 2005 Fine & Meyer	An 11-Step Program to Navigating Partnerships Commercial partnerships are an effective way to differentiate both research institutes and biotech companies. It is critical to recognize that while financial return is the primary driver of a commercial partnership, the cultural fit can sustain its success.
Pharmaceutical Executive October 1, 2005 Mark J. Ahn	It's All Academic: Biotechs Looking to Universities Pharmaceuticals and academic institutions are forming alliances at an increasing rate to exploit the promise of emerging biological insights.
Pharmaceutical Executive October 1, 2005 Joseph S. Dillon	Risks and Rewards: How to Protect the Hand You're Dealt Like each bet at the gaming table, the wagers and payoffs of pharma deals must be condsidered on their own merits, using careful due diligence to achieve a beneficial deal structure.
Pharmaceutical Executive October 1, 2005 Brad Miles	Value Today for Drugs Tomorrow The industry can help its bad rep by communicating the promise of its pipeline -- and the value of its companies.
Pharmaceutical Executive October 1, 2005 Andy Bender	Orchestrating Compliance Product managers at pharmaceuticals are not always happy to see their compliance officers. That may be changing.
Pharmaceutical Executive October 1, 2005 Chaudhry & Love	Key Opinion Leaders Interactions with Pharma Big pharmaceutical companies are paying the same key opinion leaders for many different services. All at the same time. And firms don't notice it because key opinion leaders are hidden in silos.
Pharmaceutical Executive October 1, 2005 Steve Tarnoff	Sampling: Crimes in the Closet The pharmaceutical industry's time-honored sampling practices used to be good selling strategies. Until the Office of the Inspector General called them fraud.
Pharmaceutical Executive October 1, 2005 Jill Van Den Bos	Formulary Additions: The Big Picture Product managers at pharma firms know how fiercely new drugs compete for inclusion on health plans' formularies. An actuarially sound, full-budget-impact model may be out of reach. But companies could express data in units that a health plan can integrate into its own internal actuarial analysis.
<Older 2511-2520 Newer> Return to current articles.